Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 1
Abstract
Biological (large molecule) drug products are made via living systems and are complex and variable in nature. As a result, generic forms of biological products, also termed biosimilars in the EU or follow-on biologics by the US Food and Drug Administration, can only be similar to the reference product, unlike generic versions of small molecule drug products that contain the exact same active ingredient as the brand-name drug. Compared with small molecule drug products, more stringent assessment of safety, purity, and potency is needed to show that a follow-on biologic is not clinically different from the reference biological product. This paper addresses statistical criteria for establishing biosimilarity and interchangeability of follow-on biologics as set forth by the Biologics Price Competition and Innovation Act. It also highlights the scientific issues regarding the assessment of follow-on biologics that are currently still unresolved within the US.
Authors and Affiliations
Shein-Chung Chow, Christine Ju
Keywords
Related Articles
- EP ID EP355086
- DOI 10.5639/gabij.2013.0201.004
- Views 113
- Downloads 0
Health authority perspective on biosimilars
Dr Brian Godman reviews Mr Gustaf Befrits’ paper on the case for biosimilars from a payer’s perspective. Biosimilars are increasingly important to payers with growing resource pressures. However, key issues need addressi...
Biosimilarity of anticancer monoclonal antibodies in the clinic
The European Medicines Agency recommends the use of pharmacodynamics (PD) markers when establishing biosimilarity, but no such biomarkers are known for the clinical efficacy of bevacizumab (Avastin). For this reason, con...
ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities
The International Conference on Harmonisation (ICH) has endorsed a new guideline concerning the development and manufacture of chemical and biotechnological/biological drug substances. The guideline harmonises the scient...
Commentary on the recommendations of the European Society for Organ Transplantation Advisory Committee on generic substitution of immunosuppressive drugs
In 2010, the Council of the European Society for Organ Transplantation formed an Advisory Committee to formulate recommendations on the use of generic drugs in solid organ transplant recipients. The initiative was taken...
Assuring patient-centred care: engaging patients with rheumatoid arthritis in disease monitoring and pharmacovigilance
With the advent of complex therapies in the form of biologicals, emerging biosimilars and non-biological complex drugs, monitoring for treatment related benefit and the potential for adverse effects is as critical as mon...